Bieche I, Parfait B, Tozlu S, Lidereau Roentgen, Vidaud M: Quantitation regarding androgen receptor gene expression into the sporadic nipple cancers by real-date RT-PCR: proof one MYC was an enthusiastic AR-managed gene. Carcinogenesis. 2001, 22 (9): 1521-1526. /carcin/22.nine.1521.
Bratthauer GL, Lininger RA, Child YG ourtime tanışma uygulamaları, Tavassoli FA: Androgen and you will the hormone estrogen receptor mRNA standing inside apocrine carcinomas. Diagn Mol Pathol. 2002, eleven (2): 113-118. 9606-200206000-00008.
Gatalica Z: Immunohistochemical data out of apocrine nipple sores. Uniform over-phrase away from androgen receptor followed closely by the increasing loss of estrogen and you may progesterone receptors inside apocrine metaplasia and you can apocrine carcinoma into the situ. Pathol Res Pract. 1997, 193 (11-12): 753-758.
Am J Clin Pathol
Soreide JA, Lea OA, Varhaug JE, Skarstein A great, Kvinnsland S: Androgen receptors during the operable cancer of the breast: regards to other steroid hormones receptors, correlations so you can prognostic things and predictive well worth having aftereffect of adjuvant tamoxifen therapy. Eur J Surg Oncol. 1992, 18 (2): 112-118.
Bayer-Garner IB, Smoller B: Androgen receptors: a marker to improve sensitivity having identifying cancer of the breast inside the facial skin metastasis of not familiar pri, 13 (2): 119-122. /modpathol.3880021.
Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic craft and medical ramifications. J Clin Oncol. 2000, 18 (5): 1135-1149.
Pang ST, Flores-Morales A, Skoog L, Chuan YC, Nordstedt Grams, Pousette A beneficial: Controls out of matrix metalloproteinase 13 term from the androgen from inside the prostate cancers. Oncol Rep. 2004, eleven (6): 1187-1192.
Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ: Androgen receptors in breast cancer. Cancer. 1984, 54 (11): 2436-2440. -0142(19841201)<2436::AID-CNCR2820541121>3.0.
Schippinger W, Regitnig P, Dandachi N, Wernecke KD, Bauernhofer T, Samonigg H, Moinfar F: Assessment of one’s prognostic importance of androgen receptor term during the metastatic cancer of the breast. Virchows Arc. 2006, 449 (1): 24-30. /s00428-006-0213-6.
Parker RL, Huntsman DG, Lesack DW, Cupples JB, Give DR, Akbari Yards, Gilks CB: Testing away from interlaboratory version regarding the immunohistochemical determination from the hormone estrogen receptor condition playing with a breast cancer tissues microarray. 2002, 117 (5): 723-728. /PEF8-GL6F-YWMC-AG56.
Vizoso FJ, Gonzalez LO, Corte MD, Rodriguez JC, Vazquez J, Lamelas ML, , Garcia-Muniz JL: Study of matrix metalloproteinases and their inhibitors into the cancer of the breast. Br J Cancer. 2007, 96 (6): 903-911. /sj.bjc.6603666.
Narita D, Raica Meters, Suciu C, Cimpean Good, Anghel A good: Immunohistochemical expression out-of androgen receptor and you will prostate-specific antigen in the breast cancer. Folia Histochem Cytobiol. 2006, 49 (3): 165-172.
Egeblad Yards, Werb Z: This new services on the matrix metalloproteinases inside the cancers development. Nat Rev Cancer. 2002, 2 (3): 161-174. /nrc745.
Turk V, Kos J, Turk B: Cysteine cathepsins (proteases)–towards main phase away from cancer tumors?. Cancers Cell. 2004, 5 (5): 409-410. /S1535-6108(04)00117-5.
Manes S, Llorente Meters, Lacalle RA, Gomez-Mouton C, Kremer L, Mira E, Martinez Air-conditioning: The newest matrix metalloproteinase-9 controls the new insulin-eg increases grounds-triggered autocrine impulse in the DU-145 carcinoma tissue. J Biol Chem. 1999, 274 (11): 6935-6945. /jbc..
Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel E, Matrisian LM, Mareel Meters: Release of an attack supporter E-cadherin fragment by the matrilysin and you can stromelysin-1. J Cellphone Sci. 2001, 114 (Pt step 1): 111-118.
Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM: Matrilysin [MMP-7] phrase chooses to have tissues with just minimal sensitiveness to apoptosis. Neoplasia. 2001, step 3 (6): 459-468. /sj.neo.7900190.
CO;2-H
Stetler-Stevenson WG: Matrix metalloproteinases in the angiogenesis: a relocation address for therapeutic intervention. J Clin Purchase. 1999, 103 (9): 1237-1241. /JCI6870.
Cornelius Los angeles, Nehring LC, Harding Elizabeth, Bolanowski Meters, Welgus HG, Kobayashi DK, Enter RA, Shapiro SD: Matrix metalloproteinases build angiostatin: effects for the neovascularization. J Immunol. 1998, 161 (12): 6845-6852.
Jiang Y, Goldberg ID, Shi YE: Complex jobs from tissue inhibitors regarding metalloproteinases in cancer. Oncogene. 2002, 21 (14): 2245-2252. /sj.onc.1205291.